Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

Mitsunori Ushigome, Kimihiko Funahashi, Akiharu Kurihara, Satoru Kagami, Kenichiro Arai, Hideaki Shimada, Hiroyuki Shiokawa, Hironori Kaneko, Satoshi Matsuda, Tomoaki Kaneko, Junichi Koike, Takayuki Suzuki, Significance of KRAS mutation in patients receiving mFOLFOX6 with or without bevacizumab for metastatic colorectal cancer. Hepato-gastroenterology. ,vol. 61, pp. 2222- ,(2014)

Filippo Pietrantonio, Chiara Cremolini, Fausto Petrelli, Maria Di Bartolomeo, Fotios Loupakis, Claudia Maggi, Carlotta Antoniotti, Filippo de Braud, Alfredo Falcone, Roberto Iacovelli, First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology Hematology. ,vol. 96, pp. 156- 166 ,(2015) , 10.1016/J.CRITREVONC.2015.05.016

Zev A Wainberg, Alexandra Drakaki, The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors Expert Opinion on Biological Therapy. ,vol. 15, pp. 1205- 1220 ,(2015) , 10.1517/14712598.2015.1050375

Volker Heinemann, Sebastian Stintzing, Dominik P. Modest, Clemens Giessen-Jung, Marlies Michl, Ulrich R. Mansmann, Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC) European Journal of Cancer. ,vol. 51, pp. 1927- 1936 ,(2015) , 10.1016/J.EJCA.2015.06.116

Fotios Loupakis, Chiara Cremolini, Gianluca Masi, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Enrico Cortesi, Gianluca Tomasello, Monica Ronzoni, Rosella Spadi, Alberto Zaniboni, Giuseppe Tonini, Angela Buonadonna, Domenico Amoroso, Silvana Chiara, Chiara Carlomagno, Corrado Boni, Giacomo Allegrini, Luca Boni, Alfredo Falcone, Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer The New England Journal of Medicine. ,vol. 371, pp. 1609- 1618 ,(2014) , 10.1056/NEJMOA1403108

Marc Peeters, Meinolf Karthaus, Fernando Rivera, Jan-Henrik Terwey, Jean-Yves Douillard, Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status Drugs. ,vol. 75, pp. 731- 748 ,(2015) , 10.1007/S40265-015-0386-X

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, Norbert Niederle, Andreas Rost, Heinz-Gert Höffkes, Markus Moehler, Reinhard U Lindig, Dominik P Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncology. ,vol. 15, pp. 1065- 1075 ,(2014) , 10.1016/S1470-2045(14)70330-4

Muhammad A. Khattak, Hilary Martin, Andrew Davidson, Michael Phillips, Role of First-Line Anti–Epidermal Growth Factor Receptor Therapy Compared With Anti–Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials Clinical Colorectal Cancer. ,vol. 14, pp. 81- 90 ,(2015) , 10.1016/J.CLCC.2014.12.011

Timothy J Price, Maressa A Bruhn, Chee K Lee, Jennifer E Hardingham, Amanda R Townsend, Kristy P Mann, John Simes, Andrew Weickhardt, Joseph W Wrin, Kate Wilson, Val Gebski, Guy Van Hazel, Bridget Robinson, David Cunningham, Niall C Tebbutt, Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. British Journal of Cancer. ,vol. 112, pp. 963- 970 ,(2015) , 10.1038/BJC.2015.37

Hubert Piessevaux, Marc Buyse, Michael Schlichting, Eric Van Cutsem, Carsten Bokemeyer, Steffen Heeger, Sabine Tejpar, Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab Journal of Clinical Oncology. ,vol. 31, pp. 3764- 3775 ,(2013) , 10.1200/JCO.2012.42.8532